Aridis Pharmaceuticals (ARDS) Reports AR-501 Met Primary and

Aridis Pharmaceuticals (ARDS) Reports AR-501 Met Primary and Secondary Endpoints in Phase 2a Study

Aridis Pharmaceuticals (ARDS) Reports AR-501 Met Primary and Secondary Endpoints in Phase 2a Study
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Hasan Jafri , Noah Lechtzin , Vu Truong , Professor Of Medicine At Johns Hopkins University , Adult Cystic Fibrosis Program , Aridis Pharmaceuticals , Media Communications , Aridis Pharmaceuticals Inc , Drug Administration , Cf Foundation , Cystic Fibrosis Foundation , Nasdaq , Exchange Commission , University Of Washington Seattle , European Medicines Agency , Matt Sheldonredchip Companies Inc , Investor Relationsdave Gentryredchip Companies Inc , Cystic Fibrosis , Aridi Chief Medical , Associate Professor , Johns Hopkins , Aridi Phase , Orphan Drug , Fast Track , Qualified Infectious Diseases Product , Relationsdave Gentryredchip Companies Inc ,